Global Immune Thrombocytopenia (ITP) Market Research Report Forecast to 2023

$4,450$6,250

Clear

Description

Introduction
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by improper clotting of blood. ITP can cause excessive bruising and bleeding owing to the unusually low levels of platelets or thrombocytes in the blood. ITP can occur in both children and adults. ITP can be classified as primary, i.e., occurring on its own, or secondary, occurring alongside another condition. Autoimmune diseases, chronic infections, medications, pregnancy, and certain cancers are common secondary triggers of ITP. The increasing prevalence of ITP is expected to contribute to the growth of the market over the forecast period.
The global immune thrombocytopenia (ITP) market has been segmented, by type, treatment, and end user.
Based on type, the global immune thrombocytopenia (ITP) market has been categorized as acute immune thrombocytopenia and chronic immune thrombocytopenia.
On the basis of treatment, the global immune thrombocytopenia (ITP) market is further sub-segmented into corticosteroids, thrombopoietin receptor agonists, and intravenous immunoglobulins (IVIG).
Based on end user, the market has been classified as hospitals and clinics, specialty centers, and research and academic institutes.
The global immune thrombocytopenia (ITP) market was valued at USD 1,670.9 million in 2017 and is expected to register a CAGR of 5.78% during the forecast period from 2018 to 2023.

Key Players
Some of the key players in the global immune thrombocytopenia (ITP) market are Amgen Inc., CSL Limited, Dova Pharmaceuticals, Jiangsu Hengrui Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd, Ligand Pharmaceuticals, Inc, Novartis AG, Rigel Pharmaceuticals, Inc, Shire, and Shionogi Inc.
Objectives of the Study
• To provide a detailed analysis of the market structure along with a forecast of various segments and sub-segments of the global immune thrombocytopenia (ITP) market
• To provide insights into factors influencing and affecting market growth
• To provide historical and forecast revenue of market segments and sub-segments with respect to countries
• To provide strategic profiling of key players in the market and comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market
• To provide economic factors that influence the global immune thrombocytopenia (ITP) market
• To provide a detailed analysis of the value chain and supply chain of the global immune thrombocytopenia (ITP) market
Target Audience
• Research and Development (R&D) Companies
• Academic Institutes and Universities
• Pharmaceutical Companies
• Raw Material Suppliers
• Suppliers and Distributors
• Government
• Potential Investors

Key Findings
• The global immune thrombocytopenia (ITP) market is expected to reach USD 2,361.2 million by 2023 at a CAGR of 5.78% from 2018 to 2023
• Based on type, the chronic immune thrombocytopenia segment holds the largest market share and is expected to reach USD 2,036.9 million by 2023 at a CAGR of 5.94% from 2018 to 2023
• The market in the Americas is expected to account for the largest share of the global immune thrombocytopenia (ITP) market and is projected to reach USD 1,069.8 million by 2023
• The immune thrombocytopenia (ITP) market in Asia-Pacific is projected to be the fastest-growing at a CAGR of 4.40% from 2018 to 2023
Regional Analysis
• Americas
o North America
 US
 Canada
o Latin America
• Europe
o Western Europe
 Germany
 France
 UK
 Italy
 Spain
 Rest of Western Europe
o Eastern Europe
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o Rest of Asia-Pacific
• Middle East & Africa
o Middle East
o Africa

Table of Contents

Table of Contents:

1 Report Prologue
2 Executive Summary
3 Introduction
3.1 Definition
3.2 Scope of the Study
3.3 List of Assumptions
3.4 Market Structure
4 Research Methodology
4.1 Research Process
4.2 Primary Research
4.3 Secondary Research
4.4 Market Size Estimation
4.5 Forecast Model
5 Market Dynamics
5.1 Overview
5.2 Drivers
5.2.1 Rising prevalence of Immune Thrombocytopenia (ITP)
5.2.2 Growing financial support by various private and government organizations
5.3 Restraints
5.3.1 Side effects of treatment options
5.3.2 High cost of IVIG treatment
5.4 Opportunities
5.4.1 Emerging therapies in immune thrombocytopenia
6 Market Factor Analysis
6.1 Value chain analysis
6.1.1 R&D and Designing
6.1.2 Manufacturing
6.1.3 Distribution & Sales
6.1.4 Post-Sales Monitoring
6.2 Porter’s Five Forces Model
6.2.1 Bargaining Power of Suppliers
6.2.2 Bargaining Power of Buyers
6.2.3 Threat of New Entrants
6.2.4 Threat of Substitutes
6.2.5 Intense Rivalry
7 Global Immune Thrombocytopenia (ITP) Market by Type
7.1 Overview
7.2 Acute Immune Thrombocytopenia
7.3 Chronic Immune Thrombocytopenia
8 Global Immune Thrombocytopenia (ITP) Market by Treatment
8.1 Overview
8.2 Corticosteroids
8.3 Thrombopoietin receptor agonists
8.4 Intravenous Immunoglobulins (IVIG)
9 Global Immune Thrombocytopenia (ITP) Market by End-user
9.1 Overview
9.2 Hospital & Clinics
9.3 Specialty Centers
9.4 Research and Academic Institutes
10 Global Immune Thrombocytopenia (ITP) Market by Region
10.1 Overview
10.2 Americas
10.2.1 North America
10.2.1.1 US
10.2.1.2 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 UK
10.3.1.4 Italy
10.3.1.5 Spain
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia-Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 South Korea
10.4.5 Australia
10.4.6 Rest of Asia-Pacific
10.5 Middle East & Africa
10.5.1 Middle East
10.5.2 Africa
11 Competitive Landscape
11.1 Overview
11.2 Company Share Analysis
12 Company Profiles
12.1 Amgen Inc.
12.1.1 Company Overview
12.1.2 Financial Overview
12.1.3 Products/Services Offered
12.1.4 Key Developments
12.1.5 SWOT Analysis
12.1.6 Key Strategy
12.2 CSL Limited
12.2.1 Financial Overview
12.2.2 Products/Services Offered
12.2.3 Key Developments
12.2.4 SWOT Analysis
12.2.5 Key Strategy
12.3 Dova Pharmaceuticals
12.3.1 Company Overview
12.3.2 Financial Overview
12.3.3 Products/Services Offered
12.3.4 Key Developments
12.3.5 SWOT Analysis
12.3.6 Key Strategy
12.4 F. Hoffmann-La Roche Ltd
12.4.1 Company Overview
12.4.2 Financial Overview
12.4.3 Products/Services Offered
12.4.4 Key Developments
12.4.5 SWOT Analysis
12.4.6 Key Strategy
12.5 Jiangsu Hengrui Pharmaceutical Co., Ltd.
12.5.1 Company Overview
12.5.2 Financial Overview
12.5.3 Products/Services Offered
12.5.4 SWOT Analysis
12.5.5 Key Developments
12.5.6 Key strategy
12.6 Kyowa Hakko Kirin Co., Ltd.
12.6.1 Company Overview
12.6.2 Financial Overview
12.6.3 Products/Services Offered
12.6.4 Key Developments
12.6.5 SWOT Analysis
12.6.6 Key Strategy
12.7 Ligand Pharmaceuticals, Inc.
12.7.1 Company Overview
12.7.2 Financial Overview
12.7.3 Products/Services Offered
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.7.6 Key Strategy
12.8 Novartis AG
12.8.1 Company Overview
12.8.2 Financial Overview
12.8.3 Products/Services Offered
12.8.4 Key Developments
12.8.5 SWOT Analysis
12.8.6 Key Strategy
12.9 Rigel Pharmaceuticals, Inc.
12.9.1 Company Overview
12.9.2 Financial Overview
12.9.3 Products/Services Offered
12.9.4 Key Developments
12.9.5 SWOT Analysis
12.9.6 Key Strategy
12.1 Shire
12.10.1 Company Overview
12.10.2 Financial Overview
12.10.3 Products/Services Offered
12.10.4 Key Developments
12.10.5 SWOT Analysis
12.10.6 Key Strategy
12.11 Shionogi Inc.
12.11.1 Company Overview
12.11.2 Financial Overview
12.11.3 Products/Services Offered
12.11.4 Key Developments
12.11.5 SWOT Analysis
12.11.6 Key Strategy
13 Appendix
13.1 Discussion Blue Print

Additional information

Publisher

Geography Covered

Date Published

Pages

Format